As always, first the link to the first post, where you will also find the links to all the other parts https://getqu.in/cbIOkg/

Today there are a few more details on the indicators from part 3 https://getqu.in/9XGYtO/

As described in part 3, I start my analysis with the SMA 200 / 50 / 5 daysto get an overview of the trend.

Example $UBER (+1,29 %)

For me, an important setting for the SMA is that I always use the SMA regardless of my chart setting always on a daily basis. daily basis. This means that even if I have set the chart to weekly or 4h, it always shows me the SMA on a daily basis.

Example $UBER (+1,29 %) 1h hour chart - but the SMA are still on a daily basis, not like the default setting, which always refers to the chart - then the SMAs would be calculated on a 200 / 50 / 5 hour basis!

Next, I'll get the VRVP to see the volumes. I have set the chart to the range since Uber has been in an overarching sideways phase.

I can see the price area with the highest volume and the distribution where 68% of the volume has taken place.

My VRVP settings are as follows, I adjust the line size depending on the visible range - the larger the range, the larger the number of lines.

So, I now have a good overview of the trend after a few minutes.

Now it's time to continue with the VWAP. My anchored VWAP I place it in a prominent position for me. In this case the last low before the start of the sideways phase. This is how I see the "DNA" of Uber - How does Uber behave in the statistical areas of the volume-weighted average price.

For my short-term trades, I zoom into the close range, but the anchored VWAP remains. I only switch to the 1 hour chart and the last few months.

The white circles then show potential entries and exits for me. The orange circles at the bottom show the earnings, there's always a lot of movement😁

Of course, I also look in detail at the price action, i.e. the candles per time unit.

In principle, this describes my main procedure for determining the buy/sell point.

That's it 🤷‍♂️ has been working for me for a long time with the outcome as described in part 2 https://getqu.in/TVNdpR/

Because of the overview, I have hidden the VRVP in the VWAP views, but I always leave it on for my analysis.

Example anchored VWAP with VRVP and SMA5 for the short-term trend

Example anchored VWAP with VRVP and VWAP on a weekly basisI can see where the VWAP of the current week has moved. It's also nice to see how and where the big volumes of the week have positioned themselves 😁

So, that's a bit more detail on my setup. As you can see, with a little practice and routing, you can analyze a stock in a short time. For me, such an analysis usually takes no longer than 10 minutes and I know whether a trade makes sense for me and where to place my buy and sell orders.

PS: I have found a clever script on TradingView for some of my stock screener filters. You can always display some criteria live - in the chart at the bottom right

You can find it under the indicators: Ticker Dashboard For Better Stock Selection

$ADYEN (+0,46 %)
$MMK (+0,13 %)
$MRK (-1,02 %)
$KTN (-1,25 %)
$BRBY (+1,39 %)
$OMV (+0,39 %)
$VER (-1,74 %)
$BG (-0,97 %)
$VOE (+1,47 %)
$ZAL (-1,63 %)
$VRTX (-0,33 %)
$RDC (-2,8 %)

#trading

Link to the first post https://getqu.in/cbIOkg/

I will also link all parts in the first post and pin the first post in my profile.

This part of the post is about the following 2 topics

• Trading versus Buy&Hold
• What are the requirements for trading

To Buy&Hold I don't need to explain much more here 😉 It's a well-known and proven method, particularly suitable for more passive investors or those who don't want to deal with the stock market on an ongoing basis. Start with a savings plan - "time in the market" pays off!

When trading the situation is somewhat different. Active trading is required here. "Timing the market" is the motto. With the appropriate knowledge, a careful approach, good risk management and, above all, discipline, it is far more than just "gambling" or "gambling".

When I analyze my losing trades, the cause is almost always a lack of discipline, such as impatience or poor risk management. Sounds simple, but it's not... "The spirit was willing, the flesh was weak" 🤪🤷‍♂️

Conclusion:

• B&H and trading are not mutually exclusive, but can be combined well and sensibly. Part of my trading income, for example, flows into my B&H share on an ongoing basis.

• Trading means being responsible inform - plan trade - execute trade!

• Without a genuine interest in active trading and having fun trading, this will not work. If you just follow tips or influencers, you will almost certainly end up with the ominous 80% who only lose money (if only because the timing is no longer right).

The last two points in the conclusion are a good transition to the topic "Prerequisites for trading". In my view, in addition to the points already mentioned, the following aspects are essential in order to be sustainably profitable:

• Money management
• A trading tool
• Knowledge of chart analysis "a fool with a tool is still a fool"
• Discipline

Money management:

On the subject of money management, I would like to refer you to one of my older posts. It is essentially about determining the capital investment and the position size based on the maximum acceptable loss.

A proven guideline in trading is: Never risk more than 0.5% to max. 1% of your available capital per trade. You can find details on this in the following post https://getqu.in/tzhXqc/

Trading Tool:

Since trading is all about "timing the market", there is no getting around a trading tool. There are several tools on the market, and almost all of them offer a free version to get you started. The free versions are usually not sufficient for professional trading, as important indicators and data are missing. However, they are perfectly adequate for starting out and testing a little.

Tip: Use the free trial months of the subscription models to decide for yourself whether and which paid subscriptions are of interest to you.

I use TradingView https://www.tradingview.com and I'm really happy with it. In addition to the chart tool, there are lots of functions such as share screeners, market information, watchlists, price alerts, calendars for events such as earnings and dividends and a news feed. There is also a community, but I haven't used it yet.

Tip for beginners: TradingView also offers a demo account (paper trading), where you can safely start trading and test your strategies without using real money. Paper Trading — main functionality — TradingView

If you are interested in TradingView, I can offer you a referral link (just ask for it in the comments - I don't want to actively post the link here). Then we both get 15$ each credited to the fees. PS: I am not a Finfluencer and have nothing else to do with TradingView. It is not a source of income nor the goal of these posts - it would just be the usual friend-referral.

Knowledge of chart analysis:

Well, as written above, "a fool with a tool is still a fool". Of course, you can't do it without learning and dealing with the subject. The trading tools are all very helpful, but without understanding what you are doing with them and how to use the charts, indicators or oscillators, it won't work. Fortunately, today there are lots of tutorials on YouTube, communities etc. where you can acquire knowledge free of charge.

There will be more on chart analysis in the last part of the articles when it comes to my trading setup.

Discipline:

This last point is the most important; in combination with the 3 previous points, discipline is the key to success. Even long-time traders are subject to FOMO with accompanying ill-considered or not properly analyzed trades. This often ends the way it must... "Know yourself and your trading behavior!"

Please note, this article only reflects my experience. There are many different approaches to trading - there is no right or wrong. In the end, everyone has to find a setup that suits them.

Actually, I wanted to cover the first three points today, but as this post is already quite long, I'd rather end it in the spirit of TL:TR and will cover the points "Time spent" and "Trade frequency" in the next post. Possibly also "Profit and loss trades YTD 2025", which would fit in with the trade frequency / number of trades.

PS: as I'm traveling for work for the rest of the week, there won't be any more parts until next week.

Click here for part 2

https://getqu.in/TVNdpR/

#trading

In the feed of the linked shares you will find posts from the last few days/weeks from me $UBER (+1,29 %)
$ADYEN (+0,46 %)
$MMK (+0,13 %)
$VRTX (-0,33 %)
$RDC (-2,8 %)
$KTN (-1,25 %)
$NOVO B (+0,45 %)
$MRK (-1,02 %)

$KTN (-1,25 %) Was bought last week at earnings, but is struggling at the POC. For the holding period of a few days, the spread is enough for me 😉

Even though I fundamentally think a lot of Kontron and I think it would be a good B&H stock, from a short-term trading perspective it will be exchanged for stocks where I see more potential in the coming days. Capital goes into $MMK (+0,13 %) and $VRTX (-0,33 %)

POC...price area with the highest volume in the visible area (yellow dashed line)

The yellow channel shows the standard deviation from the volume-weighted average price VWAP. The upper edge is currently almost exactly at the POC

#trading

Hi everyone,

does anyone have any info on why $VRTX (-0,33 %) is going down the tubes today?

I couldn't find anything.

Thanks in advance :)

• $VRTX (-0,33 %)
  Vertex (NASDAQ: VRTX) reported fourth quarter earnings per share (EPS) of $3.98, which was $0.04 below the analyst estimate of $4.02.

• Revenue for the quarter amounted to USD 2.91 billion, compared to the consensus estimate of USD 2.79 billion.

Guidance 2025:

• Vertex expects fiscal 2025 revenue of $11.75 billion to $12.00 billion, compared to the analyst consensus estimate of $11.85 billion.

Next week won't be boring either 🫡

There's something for everyone 😁

What numbers are you looking forward to? 🧐

$MCD (-1,13 %)
$VRTX (-0,33 %)
$KO (-0,86 %)
$SPGI (+0,34 %)
$VRT (-1,76 %)
$PANW (+1,36 %)
$CVS (-1,51 %)

$MEDP (-6,33 %)
$ACLS (-2,08 %)
$THC (+1,01 %)
$TTD (-6,78 %)
$CSCO (+0,34 %)
$APP (-2,14 %)
$HOOD (-1,42 %)
$DE (+0,19 %)
$AMAT (+1,49 %)
$ABNB (+2,16 %)

Revolution in painkillers

$VRTX (-0,33 %)

Pharma shares soar after FDA approval!

According to Vertex, this is the first new class of painkillers in over 20 years. The drug, Suzetrigine, sold under the name Journavx, is used to treat moderate to severe acute pain and costs $15.50 per 50-milligram pill.

It is taken orally twice a day. While opioids block the pain signals in the brain, Journavx acts on the nerves before the signals reach the brain. This significantly reduces the risk of addiction.

The Food and Drug Administration (FDA) found that Journavx showed "statistically significant, superior pain reduction" over placebos in two double-blind, placebo-controlled studies. These studies investigated postoperative pain after abdominoplasty and bunion surgery. Participants with inadequate pain control were also allowed to take ibuprofen.

Vertex is also evaluating the use of Suzetrigine for peripheral neuropathic pain. Analysts had expected a higher price for the drug, which is being discussed in specialist circles.

Olivia Brayer from Cantor had expected a price of 60 to 80 US dollars, but pointed out that acute pain often only requires a 14-day treatment. "Discounts for chronic pain could be much higher as there could be issues with potential access."

Evercore analysts Liisa Bayko and Saima Machlovi had expected a price of $20 to $30 per day. They see Journavx primarily as a solution for patients with addictions and obesity, as respiratory depression is a risk for them. However, the delayed onset of action of two to four hours is viewed critically. "One solution would be premedication before the operation."

According to Vertex, the drug could become a blockbuster with annual sales of over one billion US dollars. The FDA sees the approval as an important step towards providing safer alternatives to opioids.

The drug proved effective in trials, but failed to meet the secondary objective of demonstrating superior efficacy over the opioid combination hydrocodone/paracetamol.

In a separate Phase III study, more than 83 percent of patients reported that Journavx was good, very good or excellent for pain relief. In the future, an extension of the approval for chronic pain could further increase the potential of Journavx.

Author: Gina Moesing, wallstreetONLINE Editorial team

The Vertex Pharmaceuticals share is trading up +8.83% at a price of 458.5EUR on Tradegate (January 31, 2025, 12:03 pm) at the time of publication of the news.

Revolution bei Schmerzmitteln: Das gab es seit Jahrzehnten nicht: Pharma-Aktie haussiert nach FDA-Zulassung! - 31.01.2025

$VRTX (-0,33 %) Such messages provide a strong boost 🙂

Pharma is always a risk, ultimately it is difficult to assess what is happening in research, for example, or the associated risk of whether or not approval will be granted at some point. But as an addition to the portfolio, such stocks can always be a booster.

I already had Vertex in my portfolio in 2023, but was then too impatient and sold it at a small profit. However, I got back in at the end of 2024 due to the pipeline. I currently hold a position with a buy-in of €392. To hedge the position so that it doesn't run into the loss zone again, I set an SL just above the cost price after this announcement. However, I am letting Vertex continue to run with a current +17%.

https://de.investing.com/news/stock-market-news/fda-genehmigt-vertex-neuartiges-nichtopioides-schmerzmittel-fur-akute-schmerzen-93CH-2857248

Hello everyone, with Donald Trump and Elon Musk in office, I'm expecting volatile times ahead. I have therefore carried out a check on my portfolio to determine how solid my foundation (core) still is.

The following criteria were used for the check

Quality check

The quality check examines shares for the quality of the business model and the stability of the balance sheet

Enduring qualities

The long-term indicator checks whether share prices are rising steadily.

Outperformer check

Every investor is confronted with the question of whether to invest money passively in ETFs or in individual shares. A share should rise by more than 10% per year for an investment to be worthwhile.

KUV monster

When companies are hyped and everyone knows about the quality of a company, the return potential is usually low. The top 5% of the most highly valued shares according to the KUV criterion are problematic.

The following companies from my portfolio turned out to be

buy and leave.

Alphabet $GOOG (-0,36 %) Modine Manuf. $MOD (+0,46 %) Chipotle $CMG (+0,5 %)

Microsoft $MSFT (+0,71 %) Copart $CPRT (-0,74 %) Vertex $VRTX (-0,33 %)

Constellation Software $CSU (-1,18 %) Man and machine $MUM (-0,79 %)

Corcept Therap. $CORT (-1,21 %) Tetra Tech $TTI (+0,8 %) TransDigm Group $TDG (-0,53 %)

IES Holding $IESC (+0,21 %) ASML $ASML (+0,35 %)